Abstract
The concept of privileged structures/substructures (PS) is the idea that certain structural features produce biological effects more often than others. The PS method can be seen as an offspring of fragonomics, which is based on recent experimental measurements of protein-ligand interactions. If PS prove to be true, then chemical motives that enrich biological activity can be used when designing new drugs. However, PS remain controversial because we cannot be sure whether the excess of active structures does not result from an abundance in chemical libraries. In this review, we will focus, in particular, on the preferential organization of azanaphthalene scaffolds (AN) in drugs and natural products (NP), which are preferred by Nature in evolution. We will show that knowledge discovery in molecular databases can reveal interesting time-trends profiles for important classes of potentially privileged scaffolds. The chemical library of AN is dominated by monoaza-compounds, among which quinoline appears to be the most frequently investigated scaffold; however; more sophisticated database mining seems to indicate different PS patterns within the AN scaffold family.
Keywords: Azanaphthalene scaffold, chemical spaces, database mining, fragment-based design, privileged motifs
Current Medicinal Chemistry
Title:Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold
Volume: 19 Issue: 13
Author(s): J. Polanski, A. Kurczyk, A. Bak and R. Musiol
Affiliation:
Keywords: Azanaphthalene scaffold, chemical spaces, database mining, fragment-based design, privileged motifs
Abstract: The concept of privileged structures/substructures (PS) is the idea that certain structural features produce biological effects more often than others. The PS method can be seen as an offspring of fragonomics, which is based on recent experimental measurements of protein-ligand interactions. If PS prove to be true, then chemical motives that enrich biological activity can be used when designing new drugs. However, PS remain controversial because we cannot be sure whether the excess of active structures does not result from an abundance in chemical libraries. In this review, we will focus, in particular, on the preferential organization of azanaphthalene scaffolds (AN) in drugs and natural products (NP), which are preferred by Nature in evolution. We will show that knowledge discovery in molecular databases can reveal interesting time-trends profiles for important classes of potentially privileged scaffolds. The chemical library of AN is dominated by monoaza-compounds, among which quinoline appears to be the most frequently investigated scaffold; however; more sophisticated database mining seems to indicate different PS patterns within the AN scaffold family.
Export Options
About this article
Cite this article as:
Polanski J., Kurczyk A., Bak A. and Musiol R., Privileged Structures - Dream or Reality: Preferential Organization of Azanaphthalene Scaffold, Current Medicinal Chemistry 2012; 19 (13) . https://dx.doi.org/10.2174/092986712800167356
DOI https://dx.doi.org/10.2174/092986712800167356 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Dyslipidaemia for the Prevention of Stroke: Clinical
Practice Recommendations from the Lipid Association of India
Current Vascular Pharmacology Autonomic Nervous System Dysfunction in Sjogrens Syndrome
Current Rheumatology Reviews Serum Procalcitonin Levels in Febrile Patients with Systemic Autoimmune Diseases
Current Rheumatology Reviews Congenital Malformations Attributed to Prenatal Exposure to Cyclophosphamide
Anti-Cancer Agents in Medicinal Chemistry Neuropsychiatric Involvement in Systemic Lupus Erythematosus:Current Therapeutic Approach
Current Pharmaceutical Design Antiplatelet Therapy in Children: Why So Different from Adults’?
Current Pharmaceutical Design Type I Interferon as a Target of Treatment in SLE
Endocrine, Metabolic & Immune Disorders - Drug Targets Hypersensitivity Reactions to Quinolones
Current Pharmaceutical Design Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Autoantibodies Among HIV-1 Infected Individuals and the Effect of Anti-Retroviral Therapy (ART) on It
Current HIV Research Allergic and Pseudoallergic Reactions Induced by Glucocorticoids: A Review
Current Pharmaceutical Design Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
Current Alzheimer Research New Method of Inhibition of Activity of Tumor Necrosis Factor Alpha In Patients with Psoriasis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Skin Tests in the Diagnosis of Drug Hypersensitivity Reactions
Current Pharmaceutical Design Subject Index To Volume 2
Current Rheumatology Reviews Editorial [Hot Topic: Clinical Trials in ANCA Associated Vasculitis (Guest Editor: Chetan Mukhtyar)]
Current Immunology Reviews (Discontinued) The Involvement of Norepinephrine in Behaviors Related to Psychostimulant Addiction
Current Neuropharmacology Flunarizine Dihydrochloride Nanoemulsion for Migraine Nasal Drug Delivery: Fabrication, Characterization and In Vitro Study
Drug Delivery Letters Primary Antiphospholipid Syndrome and Pulmonary Hypertension
Current Pharmaceutical Design Apoptosis-Inducing Activity of the S100A8/A9 Heterodimer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry